Literature DB >> 17893117

Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome).

M M Hagleitner1, A Lankester, P Maraschio, M Hultén, J P Fryns, C Schuetz, G Gimelli, E G Davies, A Gennery, B H Belohradsky, R de Groot, E J A Gerritsen, T Mattina, P J Howard, A Fasth, I Reisli, D Furthner, M A Slatter, A J Cant, G Cazzola, P J van Dijken, M van Deuren, J C de Greef, S M van der Maarel, C M R Weemaes.   

Abstract

BACKGROUND: Immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome) is a rare autosomal recessive disease characterised by facial dysmorphism, immunoglobulin deficiency and branching of chromosomes 1, 9 and 16 after PHA stimulation of lymphocytes. Hypomethylation of DNA of a small fraction of the genome is an unusual feature of ICF patients which is explained by mutations in the DNA methyltransferase gene DNMT3B in some, but not all, ICF patients.
OBJECTIVE: To obtain a comprehensive description of the clinical features of this syndrome as well as genotype-phenotype correlations in ICF patients.
METHODS: Data on ICF patients were obtained by literature search and additional information by means of questionnaires to corresponding authors. RESULTS AND
CONCLUSIONS: 45 patients all with proven centromeric instability were included in this study. Facial dysmorphism was found to be a common characteristic (n = 41/42), especially epicanthic folds, hypertelorism, flat nasal bridge and low set ears. Hypo- or agammaglobulinaemia was demonstrated in nearly all patients (n = 39/44). Opportunistic infections were seen in several patients, pointing to a T cell dysfunction. Haematological malignancy was documented in two patients. Life expectancy of ICF patients is poor, especially those with severe infections in infancy or chronic gastrointestinal problems and failure to thrive. Early diagnosis of ICF is important since early introduction of immunoglobulin supplementation can improve the course of the disease. Allogeneic stem cell transplantation should be considered as a therapeutic option in patients with severe infections or failure to thrive. Only 19 of 34 patients showed mutations in DNMT3B, suggesting genetic heterogeneity. No genotype-phenotype correlation was found between patients with and without DNMT3B mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893117     DOI: 10.1136/jmg.2007.053397

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  47 in total

1.  Three Types of Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome Identified by Whole-Exome Sequencing in Saudi Hypogammaglobulinemia Patients: Clinical, Molecular, and Cytogenetic Features.

Authors:  Hamza A Alghamdi; Suha A Tashkandi; Eman M Alidrissi; Rawan D Aledielah; Khelad A AlSaidi; Enas S Alharbi; Murad K Habazi; Mofareh S Alzahrani
Journal:  J Clin Immunol       Date:  2018-12-03       Impact factor: 8.317

2.  DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis.

Authors:  Mrinal Y Shah; Aparna Vasanthakumar; Natalie Y Barnes; Maria E Figueroa; Anna Kamp; Christopher Hendrick; Kelly R Ostler; Elizabeth M Davis; Shang Lin; John Anastasi; Michelle M Le Beau; Ivan P Moskowitz; Ari Melnick; Peter Pytel; Lucy A Godley
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

3.  A Novel Mutation in a Critical Region for the Methyl Donor Binding in DNMT3B Causes Immunodeficiency, Centromeric Instability, and Facial Anomalies Syndrome (ICF).

Authors:  Erez Rechavi; Atar Lev; Eran Eyal; Ortal Barel; Nitzan Kol; Sarit Farage Barhom; Ben Pode-Shakked; Yair Anikster; Raz Somech; Amos J Simon
Journal:  J Clin Immunol       Date:  2016-10-12       Impact factor: 8.317

4.  Eyes on DNA methylation: current evidence for DNA methylation in ocular development and disease.

Authors:  Deborah C Otteson
Journal:  J Ocul Biol Dis Infor       Date:  2012-03-29

5.  Role of DNMT3B in the regulation of early neural and neural crest specifiers.

Authors:  Kristen Martins-Taylor; Diane I Schroeder; Janine M LaSalle; Marc Lalande; Ren-He Xu
Journal:  Epigenetics       Date:  2012-01-01       Impact factor: 4.528

6.  ICF syndrome in Saudi Arabia: immunological, cytogenetic and molecular analysis.

Authors:  Namik Kaya; Saleh Al-Muhsen; Bandar Al-Saud; Albandary Al-Bakheet; Dilek Colak; Abdulaziz Al-Ghonaium; Hasan Al-Dhekri; Hamoud Al-Mousa; Rand Arnaout; Mohammad Al-Owain; Mohammad Iqbal
Journal:  J Clin Immunol       Date:  2010-12-01       Impact factor: 8.317

7.  Clinical and Immunological Characterization of ICF Syndrome in Japan.

Authors:  Chikako Kamae; Kohsuke Imai; Tamaki Kato; Tsubasa Okano; Kenichi Honma; Noriko Nakagawa; Tzu-Wen Yeh; Emiko Noguchi; Akira Ohara; Tomonari Shigemura; Hiroshi Takahashi; Shunichi Takakura; Masatoshi Hayashi; Aoi Honma; Seiichi Watanabe; Tomoko Shigemori; Osamu Ohara; Hiroyuki Sasaki; Takeo Kubota; Tomohiro Morio; Hirokazu Kanegane; Shigeaki Nonoyama
Journal:  J Clin Immunol       Date:  2018-10-23       Impact factor: 8.317

8.  Clinical experience in T cell deficient patients.

Authors:  Theresa S Cole; Andrew J Cant
Journal:  Allergy Asthma Clin Immunol       Date:  2010-05-13       Impact factor: 3.406

9.  Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects.

Authors:  Corry M R Weemaes; Maarten J D van Tol; Jun Wang; Monique M van Ostaijen-ten Dam; Marja C J A van Eggermond; Peter E Thijssen; Caner Aytekin; Nicola Brunetti-Pierri; Mirjam van der Burg; E Graham Davies; Alina Ferster; Dieter Furthner; Giorgio Gimelli; Andy Gennery; Barbara Kloeckener-Gruissem; Stephan Meyn; Cynthia Powell; Ismail Reisli; Catharina Schuetz; Ansgar Schulz; Andrea Shugar; Peter J van den Elsen; Silvère M van der Maarel
Journal:  Eur J Hum Genet       Date:  2013-03-13       Impact factor: 4.246

Review 10.  The role of genetics in the establishment and maintenance of the epigenome.

Authors:  Covadonga Huidobro; Agustin F Fernandez; Mario F Fraga
Journal:  Cell Mol Life Sci       Date:  2013-03-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.